Subtopic Deep Dive
Pegylated Liposomal Doxorubicin Dermatotoxicity
Research Guide
What is Pegylated Liposomal Doxorubicin Dermatotoxicity?
Pegylated liposomal doxorubicin dermatotoxicity refers to palmar-plantar erythrodysesthesia (PPE) and other skin reactions induced by pegylated liposomal doxorubicin (PLD), a formulation designed to reduce cardiotoxicity while treating recurrent ovarian and breast cancers.
PLD causes PPE through doxorubicin release in sweat, as shown by Jacobi et al. (2005, 112 citations). This contrasts with conventional doxorubicin by trading lower cardiac risk for higher skin toxicity incidence. Over 10 papers in the list address PPE mechanisms and management related to liposomal formulations.
Why It Matters
PLD dermatotoxicity limits dosing in ovarian and breast cancer patients, where tolerability directly impacts treatment adherence and outcomes (Lokich and Moore, 1984, 225 citations). Mitigation strategies like topical keratolytics improve quality of life and enable higher cumulative doses (Wolf et al., 2010, 75 citations). Radiation recall reactions confined to prior irradiation sites further complicate PLD use post-radiotherapy (Burris and Hurtig, 2010, 319 citations).
Key Research Challenges
Mechanisms of PPE Induction
Doxorubicin accumulation in eccrine glands leads to sweat-mediated skin damage with PLD (Jacobi et al., 2005, 112 citations). Exact pathways remain unclear despite formulation-specific sweat release data. Differentiating PLD from other chemotherapies challenges mechanistic studies.
Dose-Limiting Toxicity Management
PPE severity increases with cumulative PLD doses, halting therapy (Farr and Safwat, 2011, 77 citations). No definitive prevention exists despite trials like pyridoxine (Chen et al., 2013, 48 citations). Balancing skin safety with anticancer efficacy requires tailored protocols.
Radiation Recall Reactions
PLD triggers acute inflammation in previously irradiated skin areas (Burris and Hurtig, 2010, 319 citations). Poor understanding delays diagnosis and intervention. ESMO guidelines emphasize awareness but lack PLD-specific strategies (Lacouture et al., 2020, 152 citations).
Essential Papers
Radiation Recall with Anticancer Agents
Howard A. Burris, Jane Hurtig · 2010 · The Oncologist · 319 citations
Abstract Radiation recall is an acute inflammatory reaction confined to previously irradiated areas that can be triggered when chemotherapy agents are administered after radiotherapy. It remains a ...
Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome
J J Lokich, CHERYL MOORE · 1984 · Annals of Internal Medicine · 225 citations
Brief Reports1 December 1984Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia SyndromeJOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.JOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.Author, Article, an...
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
Mario E. Lacouture, V. Sibaud, Peter Arne Gerber et al. · 2020 · Annals of Oncology · 152 citations
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Nilofer S. Azad, Jeanny B. Aragon‐Ching, William L. Dahut et al. · 2009 · Clinical Cancer Research · 140 citations
Abstract Purpose: Sorafenib, a vascular endothelial growth factor (VEGF) receptor-2 and RAF kinase inhibitor, commonly causes skin toxicity. We retrospectively analyzed dermatologic toxicity in pat...
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
U. Jacobi, Evguenia Waibler, P Schulze et al. · 2005 · Annals of Oncology · 112 citations
Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its Treatment
Katherina P. Farr, Akmal Safwat · 2011 · Case Reports in Oncology · 77 citations
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome, is a relatively common dermatologic toxic reaction associated with cytotoxic chemotherapy that can limit the use of such dru...
Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5
Sherry L. Wolf, Rui Qin, Smitha Menon et al. · 2010 · Journal of Clinical Oncology · 75 citations
Purpose Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis ...
Reading Guide
Foundational Papers
Start with Lokich and Moore (1984, 225 citations) for PPE definition, Jacobi et al. (2005, 112 citations) for PLD sweat mechanism, and Burris and Hurtig (2010, 319 citations) for radiation recall basics.
Recent Advances
Lacouture et al. (2020, 152 citations) for ESMO management guidelines; Wolf et al. (2010, 75 citations) for topical prevention trials applicable to PLD.
Core Methods
Sweat doxorubicin assays (Jacobi 2005); keratolytic agents like urea/lactic acid (Wolf 2010); pyridoxine prophylaxis (Chen 2013); clinical grading per ESMO (Lacouture 2020).
How PapersFlow Helps You Research Pegylated Liposomal Doxorubicin Dermatotoxicity
Discover & Search
Research Agent uses searchPapers and exaSearch to find PLD-specific PPE literature, such as Jacobi et al. (2005) on sweat doxorubicin release. citationGraph reveals connections from Lokich and Moore (1984, 225 citations) to recent guidelines. findSimilarPapers expands to 50+ related toxicities from 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract PLD dosing data from Wolf et al. (2010), then verifyResponse with CoVe checks claims against ESMO guidelines (Lacouture et al., 2020). runPythonAnalysis with pandas statistically verifies PPE incidence rates across trials; GRADE grading scores evidence strength for pyridoxine efficacy (Chen et al., 2013).
Synthesize & Write
Synthesis Agent detects gaps in PLD-specific radiation recall mitigation via contradiction flagging between Burris and Hurtig (2010) and Lacouture et al. (2020). Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate review manuscripts with exportMermaid diagrams of toxicity pathways.
Use Cases
"Analyze PPE incidence rates from PLD trials vs conventional doxorubicin."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of incidence from Jacobi 2005, Wolf 2010) → CSV export of GRADE-scored stats.
"Draft ESMO-aligned guidelines section on PLD dermatotoxicity management."
Research Agent → citationGraph (Lacouture 2020 hub) → Synthesis Agent → gap detection → Writing Agent → latexSyncCitations + latexCompile → PDF with Lacouture et al. references.
"Find code for simulating doxorubicin sweat release models."
Research Agent → paperExtractUrls (Jacobi 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox verification of sweat diffusion sims.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers on 'pegylated liposomal doxorubicin PPE' → 50+ papers → DeepScan 7-step analysis with CoVe checkpoints → structured report grading Burris (2010) evidence. Theorizer generates hypotheses on sweat-gland targeting from Jacobi (2005) + Lokich (1984). DeepScan verifies pyridoxine meta-analysis claims (Chen 2013).
Frequently Asked Questions
What defines pegylated liposomal doxorubicin dermatotoxicity?
Primarily palmar-plantar erythrodysesthesia (PPE) from doxorubicin sweat release, reducing cardiotoxicity but increasing skin reactions (Jacobi et al., 2005).
What are key methods for PPE management?
Urea/lactic acid topicals prevent capecitabine HFS and apply to PLD (Wolf et al., 2010, 75 citations); pyridoxine at 400 mg shows potential but lacks strong evidence (Chen et al., 2013).
What are foundational papers?
Lokich and Moore (1984, 225 citations) defined PPE; Jacobi et al. (2005, 112 citations) linked doxorubicin sweat release to PLD toxicity; Burris and Hurtig (2010, 319 citations) covered radiation recall.
What open problems exist?
Definitive PLD-specific PPE prevention absent; radiation recall mechanisms unclear (Burris and Hurtig, 2010); need large trials beyond pyridoxine pilots (Chen et al., 2013).
Research Chemotherapy-related skin toxicity with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pegylated Liposomal Doxorubicin Dermatotoxicity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers